Management of Hyperurecemia with the Novel Urat-1 Inhibitor, Lesinurad: A Meta-Analysis

Ameta-analysison the pharmacokinetics, pharmacodynamics, safety, efficacy, dosing, administration and use of Lesinurad, a novel URAT1 inhibitor for the management of hyperuricemia and gout.Results of randomised phase 3 trials on lesinurad shows that it is superior to xanthine oxidase inhibitors (XOIs) alone, in lowering serum uric acid to the target levels. It was also found to have a tolerable safety profile compared to other antigout therapies.Lesinuradcan be considered as a suitable add-onmedication for patients in whom XOI treatment alone is less effective in achieving target sUA levels.